Research ArticleAccepted Article
Efficacy of moderately dosed etoposide in macrophage activation syndrome - hemophagocytic lymphohistiocytosis (MAS-HLH)
AnnaCarin Horne, Tatiana von Bahr Greenwood, Samuel C.C. Chiang, Marie Meeths, Caroline Björklund, Maria Ekelund, Peter Erensjö, Stefan Berg, Stefan Hagelberg, Yenan T. Bryceson, Ulf Andersson and Jan-Inge Henter
The Journal of Rheumatology February 2021, jrheum.200941; DOI: https://doi.org/10.3899/jrheum.200941
AnnaCarin Horne
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Tatiana von Bahr Greenwood
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Samuel C.C. Chiang
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Marie Meeths
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Caroline Björklund
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Maria Ekelund
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Peter Erensjö
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Stefan Berg
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Stefan Hagelberg
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Yenan T. Bryceson
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Ulf Andersson
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Jan-Inge Henter
Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Article Information
jrheum.200941
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online February 15, 2021.
Article Versions
- You are currently viewing a Latest version of this article (February 15, 2021 - 04:00).
- latest version (July 15, 2021 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2021 The Journal of Rheumatology
Author Information
- AnnaCarin Horne,
- Tatiana von Bahr Greenwood,
- Samuel C.C. Chiang,
- Marie Meeths,
- Caroline Björklund,
- Maria Ekelund,
- Peter Erensjö,
- Stefan Berg,
- Stefan Hagelberg,
- Yenan T. Bryceson,
- Ulf Andersson and
- Jan-Inge Henter
- Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Pediatric Rheumatology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children’s Health, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, and Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Pediatric Hematology and Oncology, Umeå University Hospital, Umeå, Sweden; Department of Pediatrics, Ryhov County Hospital, Jönköping, Sweden; Department of Women´s and Children´s Health, Uppsala University, Uppsala, Sweden; Department of Pediatrics, Falun Hospital, Falun, Sweden; Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
The study was supported by grants from the Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, Cancer and Allergy Foundation of Sweden, and Region Stockholm (ALF-project) to J.I.H. and Swedish Children's Cancer Foundation, the Swedish Cancer Foundation, the Swedish Research Council, and the Swedish Foundation for Strategic Research to Y.T.B. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript.
Address correspondence to AnnaCarin Horne, Dept of Women’s and Children’s Health, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77 Stockholm, Sweden. E-mail: annacarin.horne@sll.se
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Efficacy of moderately dosed etoposide in macrophage activation syndrome - hemophagocytic lymphohistiocytosis (MAS-HLH)
AnnaCarin Horne, Tatiana von Bahr Greenwood, Samuel C.C. Chiang, Marie Meeths, Caroline Björklund, Maria Ekelund, Peter Erensjö, Stefan Berg, Stefan Hagelberg, Yenan T. Bryceson, Ulf Andersson, Jan-Inge Henter
The Journal of Rheumatology Feb 2021, jrheum.200941; DOI: 10.3899/jrheum.200941
Accepted manuscript
Efficacy of moderately dosed etoposide in macrophage activation syndrome - hemophagocytic lymphohistiocytosis (MAS-HLH)
AnnaCarin Horne, Tatiana von Bahr Greenwood, Samuel C.C. Chiang, Marie Meeths, Caroline Björklund, Maria Ekelund, Peter Erensjö, Stefan Berg, Stefan Hagelberg, Yenan T. Bryceson, Ulf Andersson, Jan-Inge Henter
The Journal of Rheumatology Feb 2021, jrheum.200941; DOI: 10.3899/jrheum.200941